{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Aspergillosis",
    "query": {
      "condition": "Aspergillosis"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 49,
    "total_pages": 5,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Aspergillosis&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-10T20:34:15.851Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01222273",
      "title": "Open-label Vitamin D Trial for Patients With Cystic Fibrosis and Allergic Bronchopulmonary Aspergillosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cystic Fibrosis",
        "Allergic Bronchopulmonary Aspergillosis"
      ],
      "interventions": [
        {
          "name": "cholecalciferol (Vitamin D3)",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "University of Pittsburgh",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2010-09",
      "completion_date": "2013-09",
      "has_results": true,
      "last_update_posted_date": "2018-03-29",
      "last_synced_at": "2026-06-10T20:34:15.851Z",
      "location_count": 2,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01222273"
    },
    {
      "nct_id": "NCT04240886",
      "title": "Open-label Study of APX001 for Treatment of Patients With Invasive Mold Infections Caused by Aspergillus or Rare Molds",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Invasive Fungal Infections"
      ],
      "interventions": [
        {
          "name": "fosmanogepix",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Basilea Pharmaceutica",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2020-01-04",
      "completion_date": "2022-05-09",
      "has_results": true,
      "last_update_posted_date": "2025-09-16",
      "last_synced_at": "2026-06-10T20:34:15.851Z",
      "location_count": 6,
      "location_summary": "Duarte, California • Durham, North Carolina",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04240886"
    },
    {
      "nct_id": "NCT04442269",
      "title": "Investigating Treatment With Dupilumab in Patients With Allergic Bronchopulmonary Aspergillosis (ABPA) (LIBERTY ABPA AIRED)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Allergic Bronchopulmonary Aspergillosis"
      ],
      "interventions": [
        {
          "name": "dupilumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 62,
      "start_date": "2020-09-15",
      "completion_date": "2024-02-09",
      "has_results": true,
      "last_update_posted_date": "2025-04-04",
      "last_synced_at": "2026-06-10T20:34:15.851Z",
      "location_count": 13,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 10 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04442269"
    },
    {
      "nct_id": "NCT04218851",
      "title": "Posaconazole (MK-5592) Intravenous and Oral in Children With Invasive Aspergillosis (IA) (MK-5592-104)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Invasive Aspergillosis"
      ],
      "interventions": [
        {
          "name": "Posaconazole IV",
          "type": "DRUG"
        },
        {
          "name": "Posaconazole PFS",
          "type": "DRUG"
        },
        {
          "name": "Posaconazole tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "2 Years to 17 Years"
      },
      "enrollment_count": 31,
      "start_date": "2020-07-02",
      "completion_date": "2023-12-18",
      "has_results": true,
      "last_update_posted_date": "2025-01-14",
      "last_synced_at": "2026-06-10T20:34:15.851Z",
      "location_count": 4,
      "location_summary": "Orange, California • San Diego, California • Chicago, Illinois + 1 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04218851"
    },
    {
      "nct_id": "NCT03816176",
      "title": "A Study to Evaluate Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Invasive Mucormycosis",
        "Invasive Aspergillosis"
      ],
      "interventions": [
        {
          "name": "Isavuconazonium sulfate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Global Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "1 Year to 17 Years"
      },
      "enrollment_count": 31,
      "start_date": "2019-08-22",
      "completion_date": "2022-12-14",
      "has_results": true,
      "last_update_posted_date": "2024-12-05",
      "last_synced_at": "2026-06-10T20:34:15.851Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • Orange, California • Washington D.C., District of Columbia + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03816176"
    },
    {
      "nct_id": "NCT03672292",
      "title": "Evaluate Safety and Efficacy of the Coadministration of Ibrexafungerp With Voriconazole in Patients With Invasive Pulmonary Aspergillosis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Invasive Pulmonary Aspergillosis"
      ],
      "interventions": [
        {
          "name": "SCY-078",
          "type": "DRUG"
        },
        {
          "name": "Voriconazole",
          "type": "DRUG"
        },
        {
          "name": "Oral Placebo Tablets",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Scynexis, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2019-01-22",
      "completion_date": "2023-03-27",
      "has_results": true,
      "last_update_posted_date": "2024-08-09",
      "last_synced_at": "2026-06-10T20:34:15.851Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts • Ann Arbor, Michigan • Winston-Salem, North Carolina",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03672292"
    },
    {
      "nct_id": "NCT00412893",
      "title": "Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Aspergillosis",
        "Invasive Fungal Infection"
      ],
      "interventions": [
        {
          "name": "Isavuconazole",
          "type": "DRUG"
        },
        {
          "name": "Voriconazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 527,
      "start_date": "2007-03-07",
      "completion_date": "2013-03-28",
      "has_results": true,
      "last_update_posted_date": "2024-12-10",
      "last_synced_at": "2026-06-10T20:34:15.851Z",
      "location_count": 11,
      "location_summary": "Birmingham, Alabama • San Francisco, California • Chicago, Illinois + 7 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Springfield",
          "state": "Illinois"
        },
        {
          "city": "Springfield",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00412893"
    },
    {
      "nct_id": "NCT03327727",
      "title": "VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis (IA) in Adults",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Invasive Aspergillosis",
        "Invasive Pulmonary Aspergillosis"
      ],
      "interventions": [
        {
          "name": "Investigational Agent: VL-2397",
          "type": "DRUG"
        },
        {
          "name": "Standard treatment: Voriconazole, Isavuconazole, or Liposomal amphotericin B",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vical",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2018-02-20",
      "completion_date": "2019-01-14",
      "has_results": false,
      "last_update_posted_date": "2019-02-27",
      "last_synced_at": "2026-06-10T20:34:15.851Z",
      "location_count": 11,
      "location_summary": "Birmingham, Alabama • La Jolla, California • Sacramento, California + 8 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Newark",
          "state": "Delaware"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03327727"
    },
    {
      "nct_id": "NCT03059992",
      "title": "Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Invasive Candidiasis",
        "Mucocutaneous Candidiasis",
        "Coccidioidomycosis",
        "Histoplasmosis",
        "Blastomycosis",
        "Chronic Pulmonary Aspergillosis",
        "Allergic Bronchopulmonary Aspergillosis",
        "Invasive Pulmonary Aspergillosis",
        "Recurrent Vulvovaginal Candidiasis",
        "Other Emerging Fungi"
      ],
      "interventions": [
        {
          "name": "Ibrexafungerp",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Scynexis, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 233,
      "start_date": "2017-04-01",
      "completion_date": "2023-08-25",
      "has_results": true,
      "last_update_posted_date": "2024-11-20",
      "last_synced_at": "2026-06-10T20:34:15.851Z",
      "location_count": 20,
      "location_summary": "Birmingham, Alabama • Sacramento, California • San Francisco, California + 16 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03059992"
    },
    {
      "nct_id": "NCT00001937",
      "title": "Comparing the Effectiveness of Fluconazole and a New Medicine (FK463) in Preventing Fungal Infections in Bone Marrow Transplant Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Aspergillosis",
        "Candidiasis",
        "Fungemia",
        "Mycoses"
      ],
      "interventions": [
        {
          "name": "FK463",
          "type": "DRUG"
        },
        {
          "name": "Fluconazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 800,
      "start_date": "1999-11",
      "completion_date": "2000-12",
      "has_results": false,
      "last_update_posted_date": "2008-03-04",
      "last_synced_at": "2026-06-10T20:34:15.851Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001937"
    }
  ]
}